out as indicated in example 1 above the results are indicated below the demographic and gout disease characteristics of study subjects are shown in table 1 below common co morbidities associated with gout including obesity hypertension coronary artery disease and renal stones were distributed relatively evenly among the 6 dosing cohorts although 3 of 4 subjects in the 4 mg cohort had type ii diabetes mellitus mean age ranged from 41 8 y in the 2 mg to 64 5 y in the 12 mg dose cohort mean body mass index ranged from 28 3 in the 2 mg to 36 5 in the 8 mg dose cohorts a history of acute gout attacks was reported by 92 of subjects flares were monoarticular in 41 oligoarticular in 27 and polyarticular in 32 chronic synovitis was present in 62 5 of subjects and 75 had tophi at screening the mean u00b1 sd serum urate concentration was 9 4 u00b1 0 9 mg dl in the 17 subjects who were not receiving antihyperuricemic medication and 6 6 u00b1 1 2 mg dl in the 7 subjects who were receiving allopurinol after the washout period puac in the latter subjects rose to 8 6 u00b1 0 8 mg dl prior to infusion of peg uricase the mean u00b1 sd puac for all 6 dose cohorts was 10 9 u00b1 0 5 mg dl range 10 7 11 8 mg dl puox was undetectable in all subjects fig1 a plots these parameters following infusion of peg uricase for the 8 mg dose cohort which had the highest baseline puac maximum post infusion puox was 26 u00b1 2 8 mu ml and the level after 21 d was 6 5 u00b1 1 1 mu ml the plasma half life.